# 2026-05620: FDA Calls for Input on Pet Drug Fee Reporting Rules

2026-05620, Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-23, effective Either electronic or written comments on the collection of information must be submitted by May 22, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05620
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05620
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 13854
- Published: 2026-03-23
- Effective: Either electronic or written comments on the collection of information must be submitted by May 22, 2026.
- Comments close: 2026-05-22
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Calls for Input on Pet Drug Fee Reporting Rules

## Summary

The FDA wants your thoughts on how it collects info about fees for animal drugs and generic animal drugs. This affects companies that pay these fees and helps the FDA keep things fair and clear. You’ve got until May 22, 2026, to share your comments, so don’t miss out on shaping the rules!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's animal drug and animal generic drug user fee programs.

## Effects PRIA read

- You must file fee cover sheets: cost, low. If you sponsor a new animal drug or an abbreviated (generic) animal drug application, you must submit a user fee cover sheet through FDA Center for Veterinary Medicine’s eSubmitter (Form FDA 3546 for animal drugs; Form FDA 3728 for generics). FDA estimates each cover sheet takes about 0.5 hours (30…
- Fee waiver and reduction requests require paperwork: cost, low. If you request a waiver or reduction of ADUFA/AGDUFA user fees, you must submit supporting information and FDA will use that information to decide the request. The notice lists waiver categories (for example: significant barrier to innovation; fees exceed cost; free-choice feeds; minor use/minor sp…
- ADUFA/AGDUFA remain in force through 2028: cost, low. The Animal Drug User Fee Act (ADUFA) and Animal Generic Drug User Fee Act (AGDUFA) programs are currently reauthorized through September 30, 2028, and FDA is engaging stakeholders on the 2028 reauthorization. That means the statutory user-fee programs and associated information collections (includi…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05620 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/23/2026-05620/agency-information-collection-activities-proposed-collection-comment-request-reporting-associated)
- [2026-05620 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05620.pdf)

## Related
- [Previous: 2026-05619, Permanent Advisory Committee To Advise the U.S. Commissioners to the Western an…](https://policyrisk.com/federal-register/2026-05619)
- [Next: 2026-05621, Application for Renewal of Authorization To Export Electric Energy; MAG Energy…](https://policyrisk.com/federal-register/2026-05621)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05620 (as of 2026-06-08).
